Table 1.

Patient demographics and baseline characteristics (FAS LOCF)

Variable	Exenatide (N = 52)	BIAsp 30 (N = 52)	P value
Male, n (%)	36 (69.23)	35 (67.37)	0.8331
Age, years	51.54 ± 9.85	51.61 ± 9.77	0.9698
Weight, kg	74.09 ± 11.22	73.56 ± 12.00	0.8162
Height, cm	167.63 ± 7.55	167.11 ± 8.45	0.7399
BMI, kg/m2	26.27 ± 3.08	26.25 ± 3.12	0.9691
Duration of T2DM, years	5.96 ± 4.15	6.09 ± 4.46	0.9689
Heart rate, beats/min	76.35 ± 6.67	76.06 ± 6.28	0.8207
SBP, mmHg	123.27 ± 10.81	123.00 ± 12.34	0.906
DBP, mmHg	79.12 ± 8.02	76.83 ± 7.51	0.1361
HbA1c, %	8.75 ± 0.74	8.81 ± 0.74	0.6422
FPG, mmol/l	9.96 ± 2.78	10.26 ± 2.76	0.574
2-h PPG, mmol/l	15.92 ± 3.90	15.89 ± 2.87	0.3627
Urinary albumin, mg/l	11.9 (2.1–1110)	18.4 (2.1–2930)	0.5084

Data were presented as n (%), mean ± SD or median (minimum, maximum) in patients who received ≥ 1 dose of study drug and had at least one follow-up visit

FAS full analysis set, LOCF last observation carried forward, BMI body mass index, T2DM types 2 diabetes mellitus, SBP systolic blood pressure, DBP diastolic blood pressure, HbA1c glycated hemoglobin, FPG fasting plasma glucose, 2-h PPG 2-h postprandial plasma glucose